Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Qingrong Huang, Shan He, Yuanyuan Tian, Yuting Gu, Pan Chen, Changhong Li, Jiefang Huang, Yongnian Liu, Hongshuang Yu, Min Jin, Shaoyan Hu, Qing Tong, Anqi Ma, Jian Jin, Elizabeth Hexner, Henry Fung, Ran Reshef, Yi Zhang, Yanyun Zhang

Blood (2017) 129 (20): 2737–2748.

https://doi.org/10.1182/blood-2016-08-735886

Published: 2017

Includes: Supplemental data

Journal Articles

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Raji Shameem, MD, Philip A. Pancari, MD, Henry Fung, MD, Lianchun Xiao, PhD, Xuelin Huang, PhD, Woonbok Chung, PhD, Hagop M. Kantarjian, MD, Jean-Pierre J. Issa, MD

Blood (2016) 128 (22): 3170.

https://doi.org/10.1182/blood.V128.22.3170.3170

Published: 2016

Journal Articles

Programming of donor T cells using allogeneic δ-like ligand 4–positive dendritic cells to reduce GVHD in mice

Kazuhiro Mochizuki, Lijun Meng, Izumi Mochizuki, Qing Tong, Shan He, Yongnian Liu, Janaki Purushe, Henry Fung, M. Raza Zaidi, Yanyun Zhang, Ran Reshef, Bruce R. Blazar, Hideo Yagita, Shin Mineishi, Yi Zhang

Blood (2016) 127 (25): 3270–3280.

https://doi.org/10.1182/blood-2015-05-644476

Published: 2016

Includes: Supplemental data

Journal Articles

Programming of Donor T Cells Using Allogeneic Delta-like Ligand 4-Positive Dendritic Cells to Reduce Gvhd but Retain GVL Activity

Kazuhiro Mochizuki, MD PhD, Lijun Meng, Izumi Mochizuki, MD, Qing Tong, MD, Shan He, Yongnian Liu, Janaki Purushe, Hongxing Sun, Henry Fung, Raza Zaidi, Ran Reshef, MD, Bruce R. Blazar, MD, Hideo Yagita, PhD, Shin Mineishi, MD, Yi Zhang

Blood (2015) 126 (23): 233.

https://doi.org/10.1182/blood.V126.23.233.233

Published: 2015

Journal Articles

Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Philip A. Pancari, MD, Henry Fung, Hagop M. Kantarjian, MD, Lianchun Xiao, Huang Xuelin, Jean-Pierre Issa, MD

Blood (2015) 126 (23): 3775.

https://doi.org/10.1182/blood.V126.23.3775.3775

Published: 2015

Journal Articles

The Notch Ligand DLL4 Derived from Human Dendritic Cells Is Critical for Promoting T Helper (Th)1 and Th17 Cell Differentiation

Lijun Meng, Zhenjiang Bai, Shan He, Kazuhiro Mochizuki, MD PhD, Janaki Purushe, Hongxing Sun, Jian Wang, Hideo Yagita, PhD, Shin Mineishi, MD, Henry Fung, Gregory A. Yanik, MD, Roberto Caricchio, Xiaoxuan Fan, Lisa M Crisalli, Ran Reshef, MD, Yanyun Zhang, Yi Zhang

Blood (2015) 126 (23): 3431.

https://doi.org/10.1182/blood.V126.23.3431.3431

Published: 2015

Journal Articles

In Vivo Expansion of Megakaryocyte Progenitors in CD26 −/ − Mice: Implications for Novel Post-Transplant Therapeutics.

Shannon Kidd, Carlos E. Bueso-Ramos, MD, Laura A. Paganessi, Henry Fung, MD, Stephanie Gregory, MD, Kent W. Christopherson, PhD

Blood (2007) 110 (11): 1188.

https://doi.org/10.1182/blood.V110.11.1188.1188

Published: 2007

Journal Articles

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

Amrita Y. Krishnan, MD, Joycelynne M. Palmer, PhD, Smita C. Bhatia, MD, MPH, Auayporn Nademanee, MD, Stephen J. Forman, MD, Andrew Raubitschek, MD, Arturo M. Molina, MD, Henry Fung, MD, Peter Falk, MD, Marilyn J. Slovak, MD, Nicole Tsai, MS, Jennifer Simpson, BA, Ravi Bhatia, MD

Blood (2007) 110 (11): 1082.

https://doi.org/10.1182/blood.V110.11.1082.1082

Published: 2007

Journal Articles

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

Amrita Krishnan, MD, Andrew Raubitschek, MD, Stephen J. Forman, MD, Henry Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter Falk, MD, Ricardo Spielberger, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Pablo Parker, MD, Warren Chow, MD, Ryoto Nakamura, MD, Auayporn Nademanee, MD

Blood (2005) 106 (11): 681.

https://doi.org/10.1182/blood.V106.11.681.681

Published: 2005

Journal Articles

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Blood (2005) 106 (8): 2896–2902.

https://doi.org/10.1182/blood-2005-03-1310

Published: 2005

Journal Articles

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study

Smita Bhatia, Leslie L. Robison, Liton Francisco, Andrea Carter, Yan Liu, Marcia Grant, K. Scott Baker, Henry Fung, James G. Gurney, Philip B. McGlave, Auayporn Nademanee, Norma K. C. Ramsay, Anthony Stein, Daniel J. Weisdorf, Stephen J. Forman

Blood (2005) 105 (11): 4215–4222.

https://doi.org/10.1182/blood-2005-01-0035

Published: 2005

Journal Articles

Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors

Amrita Krishnan, Smita Bhatia, Marilyn L. Slovak, Daniel A. Arber, Joyce C. Niland, Auayporn Nademanee, Henry Fung, Ravi Bhatia, Ashwin Kashyap, Arturo Molina, Margaret R. O'Donnell, Pablo A. Parker, Irena Sniecinski, David S. Snyder, Ricardo Spielberger, Anthony Stein, Stephen J. Forman

Blood (2000) 95 (5): 1588–1593.

https://doi.org/10.1182/blood.V95.5.1588.005k38_1588_1593

Published: 2000

Journal Articles

Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group

Blood (1997) 90 (10): 3844–3852.

https://doi.org/10.1182/blood.V90.10.3844

Published: 1997

NARROW

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Programming of donor T cells using allogeneic δ-like ligand 4–positive dendritic cells to reduce GVHD in mice

Programming of Donor T Cells Using Allogeneic Delta-like Ligand 4-Positive Dendritic Cells to Reduce Gvhd but Retain GVL Activity

Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO

The Notch Ligand DLL4 Derived from Human Dendritic Cells Is Critical for Promoting T Helper (Th)1 and Th17 Cell Differentiation

In Vivo Expansion of Megakaryocyte Progenitors in CD26 −/ − Mice: Implications for Novel Post-Transplant Therapeutics.

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study

Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors

Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only